Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05053880
Title A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Accendatech USA Inc.
Indications

glioblastoma

Therapies

ACT001 + Pembrolizumab

ACT001

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.